EP Patent

EP4559900A1 — Phentolamine mesylate and therapeutic uses thereof

Assigned to Opus Genetics Inc · Expires 2025-05-28 · 1y expired

What this patent protects

This invention provides phentolamine mesylate that exhibits a particular x-ray powder diffraction (XRPD) pattern or exhibits one or more particular XRPD peaks. The invention also provides compositions comprising the phentolamine mesylate and compositions in which the phentolamine…

USPTO Abstract

This invention provides phentolamine mesylate that exhibits a particular x-ray powder diffraction (XRPD) pattern or exhibits one or more particular XRPD peaks. The invention also provides compositions comprising the phentolamine mesylate and compositions in which the phentolamine mesylate is dissolved. The invention also provides methods for treating or preventing an ocular disease or condition, comprising administering to a subject in need thereof an effective amount of the phentolamine mesylate, a composition comprising the phentolamine mesylate or a composition in which the phentolamine mesylate is dissolved.

Drugs covered by this patent

Patent Metadata

Patent number
EP4559900A1
Jurisdiction
EP
Classification
—
Expires
2025-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Opus Genetics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.